PCT

PATENT
ATTORNEY DOCKET NO. 50026/049001

Certificate of Mailing: Date of Deposit: March 18, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis
Printed name of person mailing correspondence

Janet D'Annunzio-Ellis
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Inoue et al.	Art Unit:	To Be Assigned
Serial No.:	10/516,429	Examiner:	To Be Assigned
Filed:	November 30, 2004	Customer No.	21559
Title:	PARAMYXOVIRAL VECTORS ENCODING ANTIBODIES, AND USES THEREOF		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed with the exception of U.S. patent application publication numbers US 2002-0100066 A1, US 2002-0169306 A1, and US 2003-0170266 A1.

Under M.P.E.P. (Eighth Edition, August 2001, Revision 2, May 2004) §1893.03(g), Applicants also note that because the International Search for the present national stage application was conducted by the Japanese Patent Office, copies of the

documents cited in the International Search Report should have been provided to the U.S.P.T.O. and, therefore, copies of the following references are not enclosed:

Brösamle et al., "Regeneration of Lesioned Corticospinal Tract Fibers in the Adult Rat Induced by a Recombinant, Humanized IN-1 Antibody Fragment," *J. Neurosci.* 20(21):8061-8068 (2000).

Inouye et al., "Potent Inhibition of Human Immunodeficiency Virus Type 1 in Primary T Cells and Alveolar Macrophages by a Combination Anti-Rev Strategy Delivered in an Adeno-Associated Virus Vector," *J. Virol.* 71(5):4071-4078 (1997).

Li et al., "A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression," *J. Virol.* 74(14):6564-6569 (2000).

Liang et al., "Expression of a Biologically Active Antiviral Antibody Using a Sindbis Virus Vector System," *Mol. Immunol.* 34(12/13):907-917 (1997).

Masaki et al., "Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 But Not of Fibroblast Growth Factor-2," *Circ. Res.* 90(9):966-973 (2002).

Morimoto et al., "High Level Expression of a Human Rabies Virus-Neutralizing Monoclonal Antibody by a Rhabdovirus-Based Vector," *J. Immunol. Methods* 252(1-2):199-206 (2001).

Yu et al., "CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice," *J. Immunol.* 164(9):4564-4568 (2000).

Copies of WO 00/70070 A1 and WO 03/025570 A1, which are written in the Japanese language, are enclosed. Applicants also enclose English language translations of WO 00/70070 A1 and WO 03/025570 A1.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 18 March 2005

James D. DeCamp, Ph.D.
Reg. No. 43,580

JAN M. TITTEL, Ph.D.
Reg. No. 52,290

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/049001
		Serial No.	10/516,429
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Inoue et al.
		Filing Date	November 30, 2004
		Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))		IDS Filed	March 18, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	2002-0100066 A1	Jul. 25, 2002	Nagai et al.			
	2002-0169306 A1	Nov. 14, 2002	Kitazato et al.			
	2003-0170266 A1	Sep. 11, 2003	Kitazato et al.			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 00/70070 A1	Nov. 23, 2000	WIPO			Yes
	WO 03/025570 A1	Mar. 27, 2003	WIPO			Yes
	EP 0864645 A1	Sep. 16, 1998	EPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Brösamle et al., "Regeneration of Lesioned Corticospinal Tract Fibers in the Adult Rat Induced by a Recombinant, Humanized IN-1 Antibody Fragment," *J. Neurosci.* 20(21):8061-8068 (2000).
	Carroll et al., "Synthesis and Secretion of a Functional Antibody in a Vaccinia Virus Expression System," *Mol. Immunol.* 29(7/8):821-827 (1992).
	Inouye et al., "Potent Inhibition of Human Immunodeficiency Virus Type 1 in Primary T Cells and Alveolar Macrophages by a Combination Anti-Rev Strategy Delivered in an Adeno-Associated Virus Vector," *J. Virol.* 71(5):4071-4078 (1997).
	Li et al., "A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression," *J. Virol.* 74(14):6564-6569 (2000).
	Liang et al., "Expression of a Biologically Active Antiviral Antibody Using a Sindbis Virus Vector System," *Mol. Immunol.* 34(12/13):907-917 (1997).
	Masaki et al., "Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 But Not of Fibroblast Growth Factor-2," *Circ. Res.* 90(9):966-973 (2002).
	Morimoto et al., "High Level Expression of a Human Rabies Virus-Neutralizing Monoclonal Antibody by a Rhabdovirus-Based Vector," *J. Immunol. Methods* 252(1-2):199-206 (2001).
	Yu et al., "CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice," *J. Immunol.* 164(9):4564-4568 (2000).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.